抗利妥昔单抗抗体与膜性肾病利妥昔单抗疗效的关联
本研究纳入58例接受初始利妥昔单抗治疗的膜性肾病患者,用ELISA检测血清抗利妥昔单抗抗体(ARA)。11例(19.0%)ARA阳性,阳性者复发率高于阴性者(80.0% vs 24.1%,P=.029),Kaplan-Meier分析亦证实(P=.027)。4例ARA阳性且RTX抵抗患者经奥妥珠单抗治疗后中位4.8个月达临床缓解。
要点
- 初始RTX治疗的MN患者中19.0%出现ARA,中位9.3个月后检出。
- ARA阳性者复发率80.0%,显著高于阴性者24.1%(P=.029)。
- ARA阳性且RTX抵抗者换用奥妥珠单抗可获快速缓解。
核心结论
- 成人MN患者初始RTX治疗后ARA阳性与更高复发率相关。
- RTX抵抗且ARA阳性的患者接受奥妥珠单抗后可实现快速临床缓解。
研究设计与样本
- 纳入58例接受初始RTX治疗的膜性肾病患者,收集临床与实验室数据。
- 采用商业ELISA试剂盒检测血清ARA水平,分析ARA对临床结局的影响。
主要发现
- 58例中11例(19.0%)ARA阳性,中位检出时间为末次RTX注射后9.3个月(IQR 8.2-11.1)。
- 监测超过6个月的患者中,ARA阳性者(n=11)复发率80.0%,ARA阴性者(n=41)为24.1%(P=.029)。
- Kaplan-Meier分析证实ARA阳性与复发相关(log-rank检验,P=.027)。
- 初始RTX后6个月,ARA阳性患者B细胞水平更高(P=.021)。
- 4例RTX抵抗且ARA阳性患者经奥妥珠单抗治疗达临床缓解,中位缓解时间4.8个月(IQR 3.0-6.8)。
临床怎么用
- 对初始RTX治疗的MN患者可考虑监测ARA以评估复发风险。
- ARA阳性且RTX抵抗的患者可考虑换用奥妥珠单抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Primary membranous nephropathy (pMN) is a common cause of nephrotic syndrome in adults. Rituximab (RTX) is a first-line therapy targeting B cells; however, 30%-40% of MN patients exhibit treatment resistance or relapse. Studies have shown that anti-rituximab antibodies (ARA) may lead to RTX resistance through mechanisms such as drug neutralization. The objective of this study is to explore the relationship between the emergence of ARA and the clinical efficacy of initial RTX treatment in adult MN. METHODS: Patients with MN who received RTX therapy were included in this study. Clinical data and laboratory results of the patients were collected, and ARA levels in serum samples were measured using a commercial ELISA kit. The impact of ARA on the clinical outcomes of MN patients treated with RTX was analyzed. RESULTS: Among 58 patients with membranous nephropathy who received initial RTX treatment, 11 patients (19.0%) tested positive for ARA. ARA were identified after a median of 9.3 months (IQR 8.2-11.1) following the last RTX injection. Among the patients who received initial RTX treatment and were monitored for over 6 months, ARA-positive patients (n = 11) exhibited a higher relapse rate (80.0% vs. 24.1%, P = .029) than ARA-negative patients (n = 41), which was also confirmed by Kaplan-Meier analysis (log-rank test, P = .027). At 6 months post-initial RTX, ARA-positive patients demonstrated higher B-cell levels (p= .021). Four RTX-resistant and ARA-positive patients achieved clinical remission with obinutuzumab, with a median remission time of 4.8 months (IQR 3.0-6.8). CONCLUSION: This study confirms that adult patients with MN who are ARA positive have a higher relapse rate after initial RTX treatment. Patients who are RTX-resistant and ARA positive can achieve rapid clinical remission after receiving obinutuzumab treatment.
引用
- Wu D, Xu Z, Xu R, et al. Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy. Nephrol Dial Transplant. 2026. PMID: 41823316. doi:10.1093/ndt/gfag054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。